• In late November 2025, Zoetis Inc. announced that the European Commission granted marketing authorization for Lenivia® (izenive™), a new monoclonal antibody therapy providing up to three months of osteoarthritis pain relief in dogs after a single injection.

• This marks a significant expansion of Zoetis’s companion animal pain management portfolio, as Lenivia offers a longer duration of action and a novel binding approach compared to existing therapies.

• We’ll take a closer look at how Lenivia’s approval supports Zoetis’s approach to innovation and its potential impact on long-term growth.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

To be a Zoetis shareholder, you need to believe in the company’s continued ability to drive innovation in animal health, expand its portfolio, and capture unmet demand, especially in chronic pain management for pets. The recent approval of Lenivia introduces a differentiated product that could address adoption hurdles in the OA Pain space, but it may take time to materially shift the most important short-term catalyst, wider uptake of new therapies amid lingering market hesitancy. Competitive risk in key franchises, such as parasiticides and dermatology, remains crucial to monitor.

Among recent announcements, the October marketing authorization for Portela (relfove) in Europe, offering three-month pain relief for cats, stands out alongside Lenivia. Both launches reinforce Zoetis’s focus on long-acting biologics, directly supporting the core catalyst of expanding addressable markets and strengthening its pipeline, which is key for long-term growth and margin improvement.

By contrast, investors should pay close attention to slow adoption trends and safety concerns surrounding OA Pain products, as these factors…

Read the full narrative on Zoetis (it’s free!)

Zoetis is projected to reach $10.9 billion in revenue and $3.2 billion in earnings by 2028. This outlook assumes annual revenue growth of 5.2% and implies a $0.6 billion increase in earnings from the current $2.6 billion.

Uncover how Zoetis’ forecasts yield a $169.96 fair value, a 33% upside to its current price.

Eight members of the Simply Wall St Community placed Zoetis’s fair value estimates between US$153 and US$230 per share. While some anticipate meaningful product-driven growth ahead, persistent competitive pressures in core franchises could influence future profitability in ways many market participants view differently.